+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Age-Related Macular Degeneration Market Analysis 2019

  • ID: 4857814
  • Report
  • October 2019
  • Region: Global
  • 145 pages
  • Syngene Research
1 of 3

FEATURED COMPANIES

  • Acucela
  • Alimera Sciences, Inc.
  • Bayer Healthcare
  • F. Hoffmann-La Roche
  • Glaxosmithkline Plc
  • Novartis Ag
  • MORE
The Global Age-Related Macular Degeneration Market is expected to reach $15882.70 million by 2026 growing at a CAGR of 9.5% from 2018 to 2026. Age-related macular degeneration (AMD) is a condition wherein the macula the little central area of the retina in the eye is deteriorated. The macula is a significant component of the retina as it controls visual action. Macular health decides the people capacity to read, identify, recognise faces, drive, imagine, and perform tasks that require immaculate visual details.

Some of the factors such as increasing geriatric population and rising predominance of age-related macular degeneration are fuelling the market growth. However, increasing use of off label drugs and availability of off label therapies are restraining the market growth.

Based on the drug, lucentis segment has witnessed significant growth. Lucentis is used to treat the "wet form" of age-related macular degeneration. Lucentis is also used to treat swelling in the retina caused by diabetes or by a blockage in the blood vessels.

The key vendors mentioned are Valeant Pharmaceuticals International, Inc., Stemcells Inc., Santen Pharmaceuticals, Regeneron Pharmaceuticals, Pfizer, Inc., Ophthotech Corporation, Novartis Ag, Neurotech Pharmaceuticals, Inc., Kubota Pharmaceutical Holdings Co. Ltd, GlaxoSmithKline Plc, F. Hoffmann-La Roche, Bayer Healthcare, Alimera Sciences, Inc., Adverum Biotechnologies, Inc., and Acucela.

Drugs Covered:
  • Visudyne
  • Lucentis
  • Eylea
  • Avastin
  • Other Drugs
Types Covered:
  • Dry
  • Wet
Stages Covered:
  • Intermediate
  • Early-Stage
  • Late Stage
Age groups Covered:
  • Above 75 years
  • Above 60 years
  • Above 40 years
Route of Administrations Covered:
  • Intravitreal
  • Intravenous
Mode of Treatments Covered:
  • Surgery
  • Medication
  • Diagnosis
  • Devices
Applications Covered:
  • Woman
  • Men
End Users Covered:
  • Hospital & Clinics
  • Diagnostic Centers
  • Biotechnology Companies and Pharmaceuticals
  • Academic Research Institutes
Regions Covered:
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa
Key Questions Answered in this Report:
  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analyzed during the forecast period

*Please Note: This report will be delivered within 48 hours of ordering.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acucela
  • Alimera Sciences, Inc.
  • Bayer Healthcare
  • F. Hoffmann-La Roche
  • Glaxosmithkline Plc
  • Novartis Ag
  • MORE
1 Market Synopsis

2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources

3 Market Dynamics
3.1 Drivers
3.2 Restraints

4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Age-Related Macular Degeneration Market, By Drug
5.1 Introduction
5.2 Visudyne
5.3 Lucentis
5.4 Eylea
5.5 Avastin
5.6 Other Drugs

6 Global Age-Related Macular Degeneration Market, By Type
6.1 Introduction
6.2 Dry
6.3 Wet

7 Global Age-Related Macular Degeneration Market, By Stages
7.1 Introduction
7.2 Intermediate
7.3 Early-Stage
7.4 Late Stage

8 Global Age-Related Macular Degeneration Market, By Age group
8.1 Introduction
8.2 Above 75 years
8.3 Above 60 years
8.4 Above 40 years

9 Global Age-Related Macular Degeneration Market, By Route of Administration
9.1 Introduction
9.2 Intravitreal
9.3 Intravenous

10 Global Age-Related Macular Degeneration Market, By Mode of Treatment
10.1 Introduction
10.2 Surgery
10.3 Medication
10.4 Diagnosis
10.5 Devices

11 Global Age-Related Macular Degeneration Market, By Application
11.1 Introduction
11.2 Woman
11.3 Men

12 Global Age-Related Macular Degeneration Market, By End User
12.1 Introduction
12.2 Hospital & Clinics
12.3 Diagnostic Centers
12.4 Biotechnology Companies and Pharmaceuticals
12.5 Academic Research Institutes

13 Global Age-Related Macular Degeneration Market, By Geography
13.1 Introduction
13.2 North America
13.3 Europe
13.4 Asia Pacific
13.5 South America
13.6 Middle East & Africa

14 Strategic Benchmarking

15 Vendors Landscape
15.1 Valeant Pharmaceuticals International, Inc.
15.2 Stemcells Inc.
15.3 Santen Pharmaceuticals
15.4 Regeneron Pharmaceuticals
15.5 Pfizer, Inc.
15.6 Ophthotech Corporation
15.7 Novartis Ag
15.8 Neurotech Pharmaceuticals, Inc.
15.9 Kubota Pharmaceutical Holdings Co. Ltd
15.10 Glaxosmithkline Plc
15.11 F. Hoffmann-La Roche
15.12 Bayer Healthcare
15.13 Alimera Sciences, Inc.
15.14 Adverum Biotechnologies, Inc.
15.15 Acucela

List of Data Tables
Table 1 Global Age-Related Macular Degeneration Market Outlook, By Region (2017-2026) ($MN)
Table 2 Global Age-Related Macular Degeneration Market Outlook, By Drug (2017-2026) ($MN)
Table 3 Global Age-Related Macular Degeneration Market Outlook, By Visudyne (2017-2026) ($MN)
Table 4 Global Age-Related Macular Degeneration Market Outlook, By Lucentis (2017-2026) ($MN)
Table 5 Global Age-Related Macular Degeneration Market Outlook, By Eylea (2017-2026) ($MN)
Table 6 Global Age-Related Macular Degeneration Market Outlook, By Avastin (2017-2026) ($MN)
Table 7 Global Age-Related Macular Degeneration Market Outlook, By Other Drugs (2017-2026) ($MN)
Table 8 Global Age-Related Macular Degeneration Market Outlook, By Type (2017-2026) ($MN)
Table 9 Global Age-Related Macular Degeneration Market Outlook, By Dry (2017-2026) ($MN)
Table 10 Global Age-Related Macular Degeneration Market Outlook, By Wet (2017-2026) ($MN)
Table 11 Global Age-Related Macular Degeneration Market Outlook, By Stages (2017-2026) ($MN)
Table 12 Global Age-Related Macular Degeneration Market Outlook, By Intermediate (2017-2026) ($MN)
Table 13 Global Age-Related Macular Degeneration Market Outlook, By Early-Stage (2017-2026) ($MN)
Table 14 Global Age-Related Macular Degeneration Market Outlook, By Late Stage (2017-2026) ($MN)
Table 15 Global Age-Related Macular Degeneration Market Outlook, By Age group (2017-2026) ($MN)
Table 16 Global Age-Related Macular Degeneration Market Outlook, By Above 75 years (2017-2026) ($MN)
Table 17 Global Age-Related Macular Degeneration Market Outlook, By Above 60 years (2017-2026) ($MN)
Table 18 Global Age-Related Macular Degeneration Market Outlook, By Above 40 years (2017-2026) ($MN)
Table 19 Global Age-Related Macular Degeneration Market Outlook, By Route of Administration (2017-2026) ($MN)
Table 20 Global Age-Related Macular Degeneration Market Outlook, By Intravitreal (2017-2026) ($MN)
Table 21 Global Age-Related Macular Degeneration Market Outlook, By Intravenous (2017-2026) ($MN)
Table 22 Global Age-Related Macular Degeneration Market Outlook, By Mode of Treatment (2017-2026) ($MN)
Table 23 Global Age-Related Macular Degeneration Market Outlook, By Surgery (2017-2026) ($MN)
Table 24 Global Age-Related Macular Degeneration Market Outlook, By Medication (2017-2026) ($MN)
Table 25 Global Age-Related Macular Degeneration Market Outlook, By Diagnosis (2017-2026) ($MN)
Table 26 Global Age-Related Macular Degeneration Market Outlook, By Devices (2017-2026) ($MN)
Table 27 Global Age-Related Macular Degeneration Market Outlook, By Application (2017-2026) ($MN)
Table 28 Global Age-Related Macular Degeneration Market Outlook, By Woman (2017-2026) ($MN)
Table 29 Global Age-Related Macular Degeneration Market Outlook, By Men (2017-2026) ($MN)
Table 30 Global Age-Related Macular Degeneration Market Outlook, By End User (2017-2026) ($MN)
Table 31 Global Age-Related Macular Degeneration Market Outlook, By Hospital & Clinics (2017-2026) ($MN)
Table 32 Global Age-Related Macular Degeneration Market Outlook, By Diagnostic Centers (2017-2026) ($MN)
Table 33 Global Age-Related Macular Degeneration Market Outlook, By Biotechnology Companies and Pharmaceuticals (2017-2026) ($MN)
Table 34 Global Age-Related Macular Degeneration Market Outlook, By Academic Research Institutes (2017-2026) ($MN)
Table 35 North America Age-Related Macular Degeneration Market Outlook, By Drug (2017-2026) ($MN)
Table 36 North America Age-Related Macular Degeneration Market Outlook, By Type (2017-2026) ($MN)
Table 37 North America Age-Related Macular Degeneration Market Outlook, By Stages (2017-2026) ($MN)
Table 38 North America Age-Related Macular Degeneration Market Outlook, By Age group (2017-2026) ($MN)
Table 39 North America Age-Related Macular Degeneration Market Outlook, By Route of Administration (2017-2026) ($MN)
Table 40 North America Age-Related Macular Degeneration Market Outlook, By Mode of Treatment (2017-2026) ($MN)
Table 41 North America Age-Related Macular Degeneration Market Outlook, By Application (2017-2026) ($MN)
Table 42 North America Age-Related Macular Degeneration Market Outlook, By End User (2017-2026) ($MN)
Table 43 Europe Age-Related Macular Degeneration Market Outlook, By Drug (2017-2026) ($MN)
Table 44 Europe Age-Related Macular Degeneration Market Outlook, By Type (2017-2026) ($MN)
Table 45 Europe Age-Related Macular Degeneration Market Outlook, By Stages (2017-2026) ($MN)
Table 46 Europe Age-Related Macular Degeneration Market Outlook, By Age group (2017-2026) ($MN)
Table 47 Europe Age-Related Macular Degeneration Market Outlook, By Route of Administration (2017-2026) ($MN)
Table 48 Europe Age-Related Macular Degeneration Market Outlook, By Mode of Treatment (2017-2026) ($MN)
Table 49 Europe Age-Related Macular Degeneration Market Outlook, By Application (2017-2026) ($MN)
Table 50 Europe Age-Related Macular Degeneration Market Outlook, By End User (2017-2026) ($MN)
Table 51 Asia Pacific Age-Related Macular Degeneration Market Outlook, By Drug (2017-2026) ($MN)
Table 52 Asia Pacific Age-Related Macular Degeneration Market Outlook, By Type (2017-2026) ($MN)
Table 53 Asia Pacific Age-Related Macular Degeneration Market Outlook, By Stages (2017-2026) ($MN)
Table 54 Asia Pacific Age-Related Macular Degeneration Market Outlook, By Age group (2017-2026) ($MN)
Table 55 Asia Pacific Age-Related Macular Degeneration Market Outlook, By Route of Administration (2017-2026) ($MN)
Table 56 Asia Pacific Age-Related Macular Degeneration Market Outlook, By Mode of Treatment (2017-2026) ($MN)
Table 57 Asia Pacific Age-Related Macular Degeneration Market Outlook, By Application (2017-2026) ($MN)
Table 58 Asia Pacific Age-Related Macular Degeneration Market Outlook, By End User (2017-2026) ($MN)
Table 59 South America Age-Related Macular Degeneration Market Outlook, By Drug (2017-2026) ($MN)
Table 60 South America Age-Related Macular Degeneration Market Outlook, By Type (2017-2026) ($MN)
Table 61 South America Age-Related Macular Degeneration Market Outlook, By Stages (2017-2026) ($MN)
Table 62 South America Age-Related Macular Degeneration Market Outlook, By Age group (2017-2026) ($MN)
Table 63 South America Age-Related Macular Degeneration Market Outlook, By Route of Administration (2017-2026) ($MN)
Table 64 South America Age-Related Macular Degeneration Market Outlook, By Mode of Treatment (2017-2026) ($MN)
Table 65 South America Age-Related Macular Degeneration Market Outlook, By Application (2017-2026) ($MN)
Table 66 South America Age-Related Macular Degeneration Market Outlook, By End User (2017-2026) ($MN)
Table 67 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By Drug (2017-2026) ($MN)
Table 68 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By Type (2017-2026) ($MN)
Table 69 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By Stages (2017-2026) ($MN)
Table 70 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By Age group (2017-2026) ($MN)
Table 71 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By Route of Administration (2017-2026) ($MN)
Table 72 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By Mode of Treatment (2017-2026) ($MN)
Table 73 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By Application (2017-2026) ($MN)
Table 74 Middle East & Africa Age-Related Macular Degeneration Market Outlook, By End User (2017-2026) ($MN)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Valeant Pharmaceuticals International, Inc.
  • Stemcells Inc.
  • Santen Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Pfizer, Inc.
  • Ophthotech Corporation
  • Novartis Ag
  • Neurotech Pharmaceuticals, Inc.
  • Kubota Pharmaceutical Holdings Co. Ltd
  • Glaxosmithkline Plc
  • F. Hoffmann-La Roche
  • Bayer Healthcare
  • Alimera Sciences, Inc.
  • Adverum Biotechnologies, Inc.
  • Acucela
Note: Product cover images may vary from those shown
Adroll
adroll